---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-047704"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:02:01.984656+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# FDA approves BridgeBio's Attruby (acoramidis) for ATTR-CM to reduce CV death and hospitalization

## Summary
- Attruby is first and only approved TTR stabilizer with label specifying near-complete stabilization (≥90%).
- Phase 3 ATTRibute-CM: 42% reduction in composite ACM and recurrent CVH at Month 30; 50% reduction in cumulative CVH events.
- BridgeBio to receive $500M payment under royalty funding agreement upon approval.
- List price: $18,759.12 for 28-day supply; free for life for U.S. trial participants.
- MAA submitted to EMA; decision expected in 2025; Bayer has exclusive EU commercialization rights.

## SEC filing metadata
- accession: 0001140361-24-047704
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036124047704/0001140361-24-047704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036124047704/ef20039071_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-047704
- JSON: https://secwatch.observer/filing/0001140361-24-047704.json
- Plain text: https://secwatch.observer/filing/0001140361-24-047704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.